Schrödinger Reports 54% Revenue Growth to $54.3 Million, Net Loss Narrows

Schrödinger, Inc. reported significant financial performance improvements in its latest quarterly filing, with total revenues reaching $54.3 million for the three months ended September 30, 2025, a 54% increase from $35.3 million in the same period last year. The company's software products and services segment generated $40.9 million, up 28% year-over-year, while drug discovery revenues surged 295% to $13.5 million, driven by new collaborations and milestone achievements. Despite these gains, Schrödinger recorded a net loss of $32.8 million, a reduction from a loss of $38.1 million in the prior year, reflecting a 14% improvement in operational efficiency.

The company’s financial position has also seen notable changes, with total assets decreasing to $653.7 million from $823.2 million at the end of 2024. Current assets, including cash and cash equivalents, increased to $172.1 million, up from $147.3 million, while total liabilities decreased to $332.3 million from $401.8 million. The reduction in liabilities was primarily due to a decrease in deferred revenue, which fell from $111.9 million to $82.3 million, indicating a shift in revenue recognition patterns and customer engagement.

Strategically, Schrödinger has made significant strides in its drug discovery initiatives, including collaborations with major pharmaceutical companies. The company entered a research collaboration and license agreement with Novartis in November 2024, which includes an upfront payment of $150 million and potential milestone payments totaling up to $2.27 billion. Additionally, the company has focused on restructuring its operations, resulting in a workforce reduction of approximately 60 employees, or 7% of its total staff, aimed at improving cash burn and operational efficiency.

Operationally, Schrödinger reported a customer base expansion, with increased engagement metrics across its software solutions. The company’s software segment has seen a rise in both existing and new customers, contributing to a 54% increase in total revenues. The drug discovery segment also benefited from the initiation of new collaborations, particularly with Novartis, which has enhanced the company’s market position. As of September 30, 2025, Schrödinger had approximately 64.5 million shares outstanding, reflecting ongoing stock-based compensation and equity exercises.

Looking ahead, Schrödinger anticipates continued growth in its software and drug discovery segments, supported by its strategic collaborations and ongoing clinical trials. The company expects to leverage its computational platform to enhance drug discovery capabilities while managing operational costs effectively. However, it acknowledges the inherent risks associated with its business model, including reliance on successful collaboration outcomes and market conditions, which could impact future financial performance.